JP2009541327A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541327A5
JP2009541327A5 JP2009516564A JP2009516564A JP2009541327A5 JP 2009541327 A5 JP2009541327 A5 JP 2009541327A5 JP 2009516564 A JP2009516564 A JP 2009516564A JP 2009516564 A JP2009516564 A JP 2009516564A JP 2009541327 A5 JP2009541327 A5 JP 2009541327A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
hydrogen
aralkyl
zaz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009516564A
Other languages
English (en)
Japanese (ja)
Other versions
JP5226679B2 (ja
JP2009541327A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/014427 external-priority patent/WO2007149512A2/en
Publication of JP2009541327A publication Critical patent/JP2009541327A/ja
Publication of JP2009541327A5 publication Critical patent/JP2009541327A5/ja
Application granted granted Critical
Publication of JP5226679B2 publication Critical patent/JP5226679B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009516564A 2006-06-19 2007-06-19 酵素阻害のための化合物 Expired - Fee Related JP5226679B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81521806P 2006-06-19 2006-06-19
US60/815,218 2006-06-19
PCT/US2007/014427 WO2007149512A2 (en) 2006-06-19 2007-06-19 Peptide epoxyketones for pr0teas0me inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012241236A Division JP5740383B2 (ja) 2006-06-19 2012-10-31 酵素阻害のための化合物

Publications (3)

Publication Number Publication Date
JP2009541327A JP2009541327A (ja) 2009-11-26
JP2009541327A5 true JP2009541327A5 (enExample) 2010-07-22
JP5226679B2 JP5226679B2 (ja) 2013-07-03

Family

ID=38690245

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009516564A Expired - Fee Related JP5226679B2 (ja) 2006-06-19 2007-06-19 酵素阻害のための化合物
JP2012241236A Expired - Fee Related JP5740383B2 (ja) 2006-06-19 2012-10-31 酵素阻害のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012241236A Expired - Fee Related JP5740383B2 (ja) 2006-06-19 2012-10-31 酵素阻害のための化合物

Country Status (24)

Country Link
US (11) US7691852B2 (enExample)
EP (2) EP2484688B1 (enExample)
JP (2) JP5226679B2 (enExample)
KR (1) KR101441703B1 (enExample)
CN (1) CN101506224B (enExample)
AU (1) AU2007261345B2 (enExample)
BR (1) BRPI0713309A2 (enExample)
CA (1) CA2657213C (enExample)
CO (1) CO6241190A2 (enExample)
CY (1) CY1114518T1 (enExample)
DK (1) DK2041158T3 (enExample)
ES (1) ES2415632T3 (enExample)
IL (2) IL196064A (enExample)
MX (1) MX2008016512A (enExample)
MY (2) MY183014A (enExample)
NZ (4) NZ597545A (enExample)
PH (1) PH12012501747A1 (enExample)
PL (1) PL2041158T3 (enExample)
PT (1) PT2041158E (enExample)
RU (2) RU2450016C2 (enExample)
SI (1) SI2041158T1 (enExample)
UA (1) UA101303C2 (enExample)
WO (1) WO2007149512A2 (enExample)
ZA (2) ZA200810765B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494298T1 (de) 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
SI2030981T1 (sl) 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
JP5675629B2 (ja) * 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2011060179A1 (en) * 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) * 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8609610B2 (en) * 2011-02-18 2013-12-17 Trustees Of Dartmouth College Inhibitors of the trypsin-like site of the proteasome and methods of use thereof
AU2012222812A1 (en) * 2011-02-28 2013-05-02 Mcmaster University Treatment of cancer with dopamine receptor antagonists
WO2013009923A1 (en) * 2011-07-13 2013-01-17 Creighton University Methods of promoting neuron growth
JP6176259B2 (ja) 2012-06-29 2017-08-09 日産化学工業株式会社 立体選択的なエポキシケトン化合物の製造方法
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CA2881999A1 (en) * 2012-08-14 2014-02-20 Abdelmalik Slassi Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
KR20150068464A (ko) * 2012-10-12 2015-06-19 에프. 호프만-라 로슈 아게 매크로사이클릭 케토아미드 면역프로테아좀 억제제
AR095426A1 (es) * 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
SG11201507106PA (en) * 2013-03-14 2015-10-29 Onyx Therapeutics Inc Dipeptide and tripeptide epoxy ketone protease inhibitors
CN104174021A (zh) * 2013-05-22 2014-12-03 复旦大学附属华山医院 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途
WO2015032621A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Synthesis of peptide epoxy ketones
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
JP6551825B2 (ja) * 2014-02-10 2019-07-31 公立大学法人首都大学東京 クロマチン構造制御剤
DE102014010220A1 (de) 2014-07-10 2016-01-14 Immunologik Gmbh Mittel zur Behandlung retroviraler Infektionen
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
CN105017181B (zh) * 2015-07-02 2017-10-10 南京师范大学 卡非佐米关键中间体及其衍生物的制备方法
WO2017032487A1 (en) 2015-08-27 2017-03-02 Technische Universität München Proteasome inhibitor comprising a signal-emitting moiety
EP4006012A1 (en) 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
WO2018005781A1 (en) 2016-06-29 2018-01-04 Kezar Life Sciences Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
CA3029032C (en) 2016-06-29 2024-10-29 Kezar Life Sciences CRYSTAL SALTS OF AN IMMUNOPROTEASOME PEPTIDE INHIBITOR EPOXYCETONE
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
WO2018160717A1 (en) 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2018213263A1 (en) * 2017-05-15 2018-11-22 The Regents Of The University Of California Immunoproteasome inhibitor
CN111601597B (zh) 2017-08-23 2023-10-13 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
JP7344486B2 (ja) 2018-03-30 2023-09-14 国立大学法人京都大学 心筋細胞成熟促進剤
WO2021108705A2 (en) * 2019-11-25 2021-06-03 Cornell University Nuclear factor kappa b pathway inhibition to arrest calcific aortic stenosis
JP2023545031A (ja) * 2020-10-05 2023-10-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 血液疾患および固形腫瘍の処置のためのｌｍｐ７選択的阻害剤

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en) 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HUT62312A (en) 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) * 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
TW380137B (en) 1994-03-04 2000-01-21 Merck & Co Inc Process for making an epoxide
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DE19505263A1 (de) 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
EP1136498A1 (en) 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6099851A (en) 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU762373B2 (en) 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
JP2003528039A (ja) 1999-10-20 2003-09-24 オステオスクリーン，インコーポレイテッド 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
ES2272558T3 (es) 2000-10-12 2007-05-01 Viromics Gmbh Inhibidores del proteasoma para el tratamiento de infecciones causadas por virus de la hepatitis.
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
ES2278049T3 (es) 2001-05-21 2007-08-01 Alcon, Inc. Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
WO2003033506A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Aminoborane acid derivative and proteasome inhibitory drug containing the same
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
US20040116329A1 (en) 2002-01-29 2004-06-17 Epstein Stephen E. Inhibition of proteasomes to prevent restenosis
AU2003220685A1 (en) 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2003101481A1 (en) 2002-06-03 2003-12-11 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
US20030224469A1 (en) 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
US20040167139A1 (en) 2002-07-26 2004-08-26 Potter David A. Methods of treating cancer
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
MXPA05005923A (es) 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
CA2707750A1 (en) 2003-04-08 2004-10-21 Novartis Ag Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
JP4653103B2 (ja) 2003-06-10 2011-03-16 ザ ジェイ．ディヴィッド グラッドストン インスティテューツ レンチウイルス感染症を治療するための方法
US7012063B2 (en) 2003-06-13 2006-03-14 Children's Medical Center Corporation Reducing axon degeneration with proteasome inhibitors
WO2005065435A2 (en) 2003-12-31 2005-07-21 Cydex, Inc. Et Al. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
ATE494298T1 (de) 2004-04-15 2011-01-15 Proteolix Inc Verbindungen zur proteasomenzymhemmung
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
SI2030981T1 (sl) 2004-05-10 2014-11-28 Onyx Therapeutics, Inc. Spojine za inhibiranje proteasomskega encima
AU2005243140A1 (en) 2004-05-10 2005-11-24 Proteolix, Inc. Synthesis of amino acid keto-epoxides
EP2100899A3 (en) 2004-10-20 2009-09-30 Proteolix, Inc. Compounds for proteasome enzyme inhibition
EP2261236B1 (en) 2004-12-07 2015-07-15 Onyx Therapeutics, Inc. Composition for proteasome inhibition
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
EP1876893B1 (en) 2005-04-15 2012-04-11 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
WO2008033807A2 (en) 2006-09-13 2008-03-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer
MX2009007777A (es) 2007-01-23 2009-12-16 Gloucester Pharmaceuticals Inc Terapia de combinacion que comprende romidepsina y bortezomib.
JP4325683B2 (ja) 2007-02-14 2009-09-02 セイコーエプソン株式会社 画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
KR20140042933A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2212334B1 (en) 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009067453A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor

Similar Documents

Publication Publication Date Title
JP2013521295A5 (enExample)
JP2013507434A5 (enExample)
JP2012513416A5 (enExample)
TNSN08446A1 (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
RU2012103671A (ru) Пептидные эпоксикетоны для ингибирования протеасомы
RU2013158933A (ru) Новые модуляторы иммунной системы родственные заявки
JP2016537382A5 (enExample)
RU2014124028A (ru) Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
JP2016504365A5 (enExample)
JP2013531029A5 (enExample)
JP2011513305A5 (enExample)
AR060623A1 (es) Compuestos derivados de 2-azetidinona y un metodo de preparacion
JP2010515731A5 (enExample)
AR079486A1 (es) Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas.
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2016510000A5 (ja) 治療用化合物
JP2017503760A5 (enExample)
JP2016540028A5 (enExample)
MX360667B (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
JP2016529315A5 (enExample)
JP2015500842A5 (enExample)
MX2021011286A (es) Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
EP3296309A8 (en) Galactopyranosyl derivatives useful as medicaments